Resources
News
November 1, 2021
AlivaMab Discovery Services Expands Discovery Agreement with IGM Biosciences
Expanded agreement aims to accelerate the discovery of next-generation antibody modalities SAN DIEGO, Calif. – November 1, 2021 – AlivaMab Discovery ...
CONTINUE READING
CONTINUE READING
September 14, 2021
AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals
Agreement aims to accelerate the discovery of new therapeutics SAN DIEGO, Calif. – September 14, 2021 – AlivaMab Discovery Services (“ADS”), a ...
CONTINUE READING
CONTINUE READING
May 12, 2021
AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department
Jonah Rainey, Ph.D., joins ADS to bring new breadth and depth of capabilities and expertise in discovering therapeutic antibody modalities ...
CONTINUE READING
CONTINUE READING
December 14, 2020
AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment
Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development SAN DIEGO, Calif ...
CONTINUE READING
CONTINUE READING
June 3, 2020
AlivaMab Discovery Services (ADS) Announces Agreement with Tanabe Research Laboratories USA
ADS announces integrated antibody drug discovery collaboration SAN DIEGO, Calif. – June 3, 2020 – AlivaMab Discovery Services, LLC, a ...
CONTINUE READING
CONTINUE READING
May 20, 2020
AlivaMab Discovery Services Announces Planned Leadership Transition
Article Highlights Larry Green, PhD transitions from chief executive officer (CEO) to chairman, board of directors Justin Mika to succeed ...
CONTINUE READING
CONTINUE READING
April 22, 2020
Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies
Offers unique resources for COVID-19 therapeutic discovery SAN DIEGO and EMERYVILLE, Calif. – April 22, 2020 – Ablexis, LLC, AlivaMab ...
CONTINUE READING
CONTINUE READING
September 16, 2019
AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen
ADS to provide expertise and capabilities in antibody drug discovery SAN DIEGO, Calif. – September 16, 2019 – AlivaMab Discovery ...
CONTINUE READING
CONTINUE READING
February 26, 2019
AlivaMab Discovery Services Identifies Highly Potent Antibodies in Two Months for Inaugural Client Project
Company Expands Team with Veterans of Antibody Discovery and Development SAN DIEGO, Calif. – February 26, 2019 – AlivaMab ...
CONTINUE READING
CONTINUE READING
Case Studies
From Novel Assay Development to Quality Therapeutic Leads on a Rapid Timeline
This case study details AlivaMab Discovery Services delivering high affinity antibody drug candidates for a virtual client.
CONTINUE READING
CONTINUE READING
Breaking Immune Tolerance to Generate Highly Potent Cross-Reactive Antibodies
This case study shows AlivaMab Discovery Services breaking immune tolerance to create antibodies against conserved targets.
CONTINUE READING
CONTINUE READING
Generating Diverse Antibodies Against Multi-Spanning Membrane Protein Targets
This case study demonstrates how AlivaMab Discovery Services can overcome challenges of membrane protein drug development.
CONTINUE READING
CONTINUE READING
Webinars & Presentations
Foundational Antibody Discovery for Advanced Therapeutic Modalities
Learn how we address the increased challenges and complexities in discovering and developing multi-specifics and other next-generation antibody modalities.
WATCHExperience Matters: Creative Solutions to Overcome Challenges in Antibody Drug Discovery
Watch as we present data highlighting some of our antibody discovery approaches for challenging targets to yield diverse leads.
WATCHImproving Antibody Drug Candidate Success Through Developability Assessments
Learn about tools and techniques used by AlivaMab Discovery Services to de-risk the transition from discovery to development.
WATCHMaximizing Efficiencies and De-Risking Lead Selection in Antibody Drug Discovery
Learn how AlivaMab Discovery Services and Ablexis’ AlivaMab® Mouse accelerate antibody drug discovery and development.
WATCHFeatures & Interviews
Profile from Nature’s BioPharma Dealmakers September 2021
Ablexis and AlivaMab Discovery Services. Unparalleled success in antibody discovery and development.
DOWNLOADNature speaks to Larry Green, Founder and Executive Chairman
Harnessing platform technology and expertise to fuel antibody drug discovery
DOWNLOAD